Research Paper
A controlled trial of colchicine in primary biliary cirrhosis: Trial design and preliminary report

https://doi.org/10.1016/S0168-8278(87)80053-3Get rights and content

Summary

Colchicine (1 mg/day), or an identical placebo, was given to 64 patients with primary biliary cirrhosis in a double-blind controlled trial. Due to a novel, pair-matched trial design, the two groups were exceptionally well matched at entry. In comparison with placebo, colchicine produced a beneficial effect on serum albumin and bilirubin levels at 3 months in patients who had abnormal liver function (bilirubin <20 μmol/l) at entry: (albumin, P = 0.047; bilirubin, P = 0.022). In patients with normal liver function at entry (bilirubin <20 μmol/l) beneficial effects were noted on total globulin levels at 3 months (P = 0.013) and on immunoglobulin G levels at 3 and 6 months (P = 0.044 and 0.001, respectively). At 18 months, survival estimates in the colchicine and placebo groups were 84% and 69%, respectively. The difference did not reach significance. Colchicine produced an early improvement in liver function and immunoglobulin levels. Few serious side effects were encountered, and colchicine clearly merits long-term study in the treatment of primary biliary cirrhosis.

References (31)

  • RouthierG et al.

    The effects of cyclosporin A on suppressor and inducer T-lymphocytes in primary biliary cirrhosis

    Lancet

    (1980)
  • ThomasHC

    Potential pathogenic mechanisms in primary biliary cirrhosis

    Semin Liver Dis

    (1981)
  • Al-AghbarMN et al.

    In vitro effect of Cyclosporin A on immunoglobulin production and concanavalin A induced suppression in primary biliary cirrhosis

    Gut

    (1986)
  • ScheuerP

    Primary biliary cirrhosis

  • MatloffDS et al.

    A prospective trial of d-penicillamine in primary biliary cirrhosis

    N Engl J Med

    (1982)
  • Cited by (126)

    • Management of Autoimmune and Cholestatic Liver Disorders

      2009, Clinics in Liver Disease
      Citation Excerpt :

      Colchicine inhibits microtubule polymerization by binding to tubulin, ultimately preventing mitosis. Its mechanism of action in the treatment of PBC remains unknown, but it has been studied in several small studies with varying degrees of success.55–58 Although there was improvement in serum biochemical parameters, there was no histologic improvement or survival benefit seen except in the trial by Kaplan and colleagues.

    View all citing articles on Scopus
    *

    Present address: Liver Unit, King's College Hospital, London, U.K.

    View full text